

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 March 2012 (01.03.2012)

(10) International Publication Number  
**WO 2012/027237 A1**

PCT

(51) International Patent Classification:

*A61K 31/221* (2006.01) *A61P 9/04* (2006.01)  
*A61K 31/41* (2006.01) *A61P 9/12* (2006.01)  
*A61P 9/00* (2006.01)

(21) International Application Number:

PCT/US2011/048542

(22) International Filing Date:

22 August 2011 (22.08.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/376,417 24 August 2010 (24.08.2010) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALBRECHT, Diego** [CH/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **CHANDRA, Priyamvada** [US/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936-1080 (US). **GODTFREDSEN, Sven** [DK/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936-1080 (US). **JORDAAN, Pierre** [ZA/CH]; Novartis Pharma AG, Postfach, CH-Basel 4002 (CH). **LEFKOWITZ, Martin** [US/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936-1080 (US).

(74) Agent: **MAJKA, Joseph**; Novartis, Patent Department, One Health Plaza, Bldg. 101, East Hanover, New Jersey 07936-1080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY

(57) Abstract: The invention relates to methods and pharmaceutical compositions for treating hypertension and/or preventing or treating heart failure in a mammal receiving anti-coagulant therapy using compound(s) which are therapeutically effective but do not impact the pharmacokinetic or the pharmacodynamic effect(s) of the anti-coagulant, such as warfarin.



WO 2012/027237 A1